New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies
ID: 359200Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359200
Timeline
    Description

    The National Institutes of Health (NIH) is announcing a funding opportunity titled "New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies," aimed at advancing research in diabetes control systems. This initiative seeks to overcome barriers to effective open- and closed-loop diabetes management through innovative approaches, including the development of AI/machine learning-driven tools, novel hormone delivery methods, and digital twin modeling to enhance decision support systems. With an estimated total program funding of $3 million, the NIH anticipates awarding approximately six grants, with applications expected to open in September 2025 and close by October 2025. Interested applicants can reach out to Guillermo Arreaza-Rubín at ga96b@nih.gov or call 301-594-4724 for further information.

    Point(s) of Contact
    Guillermo Arreaza-Rubín National Institute of Diabetes and Digestive and Kidney Diseases
    (301) 594-4724
    ga96b@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trial Required)." This initiative aims to explore the efficacy and clinical effectiveness of multimodality digital health technology approaches, such as continuous glucose monitoring and telemedicine, in the remote management of diabetes. The research is crucial for enhancing the understanding of diabetes management, prevention, diagnosis, and treatment, with a focus on improving health outcomes. The NIH anticipates awarding three grants for projects lasting up to five years, with application deadlines set for November 7, 2025, and October 6, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the detailed announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-315.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) aimed at advancing research on the application of digital health technology in managing Type 2 Diabetes (T2D). This initiative seeks to solicit applications that explore the use of FDA-cleared digital health technologies, such as continuous glucose monitoring, telemedicine, and mobile health applications, to enhance patient engagement, improve health outcomes, and address barriers to care in diabetes management. The opportunity is particularly significant as it aims to establish a rigorous evidence-based foundation for multimodal digital health interventions, which are currently lacking. Interested applicants, particularly from private institutions of higher education, are encouraged to begin forming collaborations and developing responsive projects, with the estimated synopsis post date set for September 12, 2025, and the application submission period expected to close on October 13, 2025. For further inquiries, potential applicants can contact Dr. Henry B. Burch at henry.burch@nih.gov or by phone at 301-827-0827.
    Single Source for Establishing Pilot/Opportunity program for AI Models to Accelerate Diabetes Research (U24- Clinical Trials not allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "Single Source for Establishing Pilot/Opportunity program for AI Models to Accelerate Diabetes Research." This initiative aims to establish a pilot funding program at the University of California, San Diego, focusing on the development and validation of AI models to address the complexities of diabetes research, particularly its heterogeneity. The program seeks to integrate data science expertise into diabetes research, fostering multidisciplinary teams to create user-friendly AI models and use cases that demonstrate their potential in accelerating research efforts. Interested applicants can reach out to Dr. Xujing Wang at xujing.wang@nih.gov or by phone at 301-451-2862 for further information. The estimated project start date is February 1, 2027, with applications peer-reviewed and only meritorious submissions considered for funding.
    Collaborative Awards to Support Microphysiological System Pilot Studies in Type 2 Diabetes Research
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Collaborative Awards to Support Microphysiological System Pilot Studies in Type 2 Diabetes Research." This initiative aims to solicit applications for research focused on microphysiological systems (MPSs) that model type 2 diabetes, encouraging collaborative investigations that combine expertise in bioengineering, diabetes biology, and human metabolism. The program is particularly significant as it seeks to advance understanding of metabolic tissue interactions and the heterogeneity of type 2 diabetes, supporting small pilot studies to generate preliminary data. The estimated total funding for this program is $1,000,000, with four awards expected, and interested applicants can reach out to Dr. Albert J. Hwa at albert.hwa@nih.gov or by phone at 301-451-1525 for further information. The application process is anticipated to open with a synopsis posted on April 1, 2026, and close on July 5, 2026, with awards expected to be made in January 2027.
    Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for collaborative research projects focused on type 1 diabetes, specifically utilizing biosamples and data from established clinical studies. The objective is to advance the understanding of the disease's etiology and pathogenesis, with funding available for studies that aim to explore disease mechanisms, delay onset, and improve prevention strategies. A total of $5.5 million is committed for up to four awards in Fiscal Years 2026 and 2027, with application deadlines beginning on May 26, 2025, and a final submission date of March 9, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (R01 - Clinical Trial Not Allowed)" aimed at advancing research in the engineering of stem cell-derived islet cells specifically for Type 1 Diabetes therapies. This grant seeks to support studies that enhance the intrinsic characteristics of these islet cell products, which are derived from well-defined cell bank sources, to improve graft viability and function through optimized banking, manufacturing, and quality control processes. With an estimated total program funding of $3 million and an award ceiling of $500,000, the NIH anticipates awarding approximately six grants, with applications due by March 7, 2026. For further inquiries, interested applicants can contact Albert Hwa at NIDDKDEM@nih.gov.
    Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies," aimed at advancing research in stem cell-derived islet cell products for enhanced cell replacement therapy outcomes. This initiative seeks to stimulate studies focused on engineering the inherent characteristics of these products, which are derived from well-defined cell bank sources, to improve graft viability and function, particularly in the context of type 1 diabetes. The estimated total program funding is $3 million, with approximately six awards expected, and interested applicants are encouraged to prepare collaborative proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release on August 1, 2025. For further inquiries, potential applicants can contact Dr. Albert J. Hwa at albert.hwa@nih.gov or by phone at 301-451-1525.
    Notice of Intent to Publish a Funding Opportunity Announcement for Diabetes Research Centers (P30 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for Diabetes Research Centers (P30 Clinical Trial Optional), aimed at enhancing research collaboration and innovation in diabetes and related metabolic disorders. This initiative seeks to establish a community of preclinical and clinical researchers, providing access to specialized resources and a Pilot and Feasibility Program to foster significant advancements beyond individual project capabilities. With an estimated total program funding of $18.2 million and an award ceiling of $1 million, the NIH anticipates making approximately seven awards, encouraging applications from a diverse range of eligible entities, including non-domestic institutions and community-based organizations. Interested parties should prepare for the application process, as the estimated synopsis post date is July 30, 2025, with applications expected to be solicited by March 11, 2026, and awards anticipated by December 30, 2026. For further inquiries, contact Dr. Christopher J. Lynch at lynchcj@nih.gov or call 301-325-4232.
    PRIMED-AI: Translating Models to Clinic (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "PRIMED-AI: Translating Models to Clinic," aimed at developing innovative AI-based tools that integrate clinical imaging with multimodal health data to enhance personalized medicine for patients with chronic conditions. This initiative, part of the Precision Medicine with Artificial Intelligence program, will utilize a biphasic mechanism focusing initially on rigorous AI model building through the analysis of large datasets, with successful projects advancing to evaluate the clinical utility of AI-driven Clinical Decision Support tools. The estimated total program funding is $10.2 million, with applications expected to be solicited after the synopsis posting on July 1, 2025, and a closing date anticipated on November 1, 2025. Interested applicants can contact Dr. Sahana N. Kukke at ODPRIMED-AI@od.nih.gov or by phone at 301-402-3756 for further information.
    Diabetes Research Centers (P30 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Diabetes Research Centers (P30 Clinical Trial Optional) grant, aimed at enhancing national research efforts in diabetes and related diseases. This funding opportunity encourages collaboration among basic and clinical investigators by providing shared technical resources and a Pilot and Feasibility Program, with a focus on innovative approaches and synergies with other NIDDK-funded programs. Eligible applicants include various higher education institutions, nonprofits, and government entities, with a maximum funding amount of $1 million per year, and a total estimated program funding of $18.2 million for approximately seven awards. Interested parties should note that the application deadline is January 27, 2027, and can reach out to the Division of Diabetes, Endocrinology and Metabolic Diseases at NIDDKDEM@nih.gov for further information.